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HIVMolluscum contagiosum poxvirus (MCV) type 1 and type 2 encode two chemokine-like proteins MC148R1 and
MC148R2. It is believed that MC148R proteins function by blocking the inﬂammatory response. However, the
mechanism of the proposed biological activities of MC148R proteins and the role of the additional C-terminal
cysteines that do not exist in other chemokines are not understood. Here, we demonstrated in two different
assay systems that His-tagged MC148R1 displaces the interaction between CXCL12α and CXCR4. The N-
terminal cysteines but not the additional C-terminal cysteines modulate this displacement. His-tagged
MC148R1 blocked both CXCL12α-mediated andMIP-1α-mediated chemotaxis. In contrast, MC148R2 blocked
MIP-1α-mediated but not CXCL12α-mediated chemotaxis. Immunoprecipitation by antibodies to MC148R1
or CXCL12α followed by immunoblotting and detection by antibodies to the other protein demonstrated
physical interaction of His-tagged CXCL12α and His-tagged MC148R1. Interaction with chemokines might
mask the receptor interaction site resulting in decreased binding and impairment of the biological activities.uclear cells; Env, envelope
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Chemotactic cytokines (chemokines) are small proteins (70–100
amino acid residues) with well-characterized three-dimensional
structures usually stabilized by two disulﬁde bridges. Chemokines
are involved in attracting and activating distinct leukocyte subsets
(reviewed in (Fernandez and Lolis, 2002)). They exert their function
through interacting with the seven-transmembrane (7TM) G-protein
coupled receptors (GPCR). Chemokines are classiﬁed into four
different families on the basis of the pattern of the conserved two
N-terminal cysteine residues that form disulﬁde bridges with the two
C-terminal cysteines of the molecules. In CC chemokines, the two N-
terminal cysteines are adjacent; in CXC chemokines the two cysteines
are separated by a single amino acid; and in CX3C chemokines the
cysteines are separated by three amino acids. The XC family has only
one cysteine near the N-terminus. Chemokines have similar three-
dimensional structures comprising an N-terminal unstructuredregion, three antiparallel β-strands connected by loops, and a carboxyl
terminal α-helix (Clore and Gronenborn, 1995). Previous studies on
structure-function of chemokines determined that the ﬁrst ﬁve amino
acids constitute the activation site and the next ﬁve constitute the
receptor-binding site (reviewed in (Fernandez and Lolis, 2002)).
Some viruses have evolved novel anti-chemokine strategies to
evade the host immune system (Murphy, 2000). Anti-chemokines
comprise a major group of virus-encoded chemokine modulators and
consist of three groups based on structure and mechanism of action:
1) chemokine receptor homologues, 2) chemokine-binding protein,
and 3) chemokine homologues. Herpesviruses and poxviruses have
been found to encode proteins that target the human chemokine
system. The biological activity of these virus-encoded proteins could
represent a viral strategy to subvert immunity impairing the
generation of an effective anti-viral immune response (reviewed in
(Murphy, 2000)).Molluscum contagiosum virus (MCV) is a member of
the poxvirus family that produces small, papular tumors in the skin of
immunocompetent children and young adults and opportunistic
infections in immunodeﬁcient AIDS patients (Gur, 2008). MCV
infection occurs as a late manifestation of HIV-1 infection and is a
cutaneous correlate of cellular immune deﬁciency. It has been
proposed that MCV inhibits the activity of chemokines that bind to
speciﬁc G protein-coupled membrane receptors and recruit leuko-
cytes to areas of infection and injury (Alcami et al., 1998; Lalani et al.,
1998; Smith et al., 1997). The discovery of an ORF sequence (MC148R)
encoding a CC chemokine homologue, within the 190,000-bp genome,
provided a clue to the mechanism used to prevent an inﬂammatory
response (Senkevich et al., 1996).
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reading frames (ORF), MC148R1 and MC148R2 respectively, which
code for two 104 amino acid chemokine-like proteins (Damon et al.,
1998; Krathwohl et al., 1997). The literature reported contradictory
ﬁndings in terms of MC148R1 activity. Two groups independently
demonstrated that MC148R2 and/or MC148R1 could inhibit the
chemotaxis induced by various CC and CXC chemokines (Damon et al.,
1998; Krathwohl et al., 1997). These studies implicated a broad-
spectrum effect for MC148R1 on CC and CXC chemokine receptors.
MC148R1 puriﬁed from vaccinia-infected cells has been shown to
bind CCR2 but not CCR8. Interestingly, MC148R1 inhibited calcium
mobilization through CCR2 and CCR8 (Damon et al., 1998). However,
MC148R1 puriﬁed from transfected monkey COS-7 cells showed
speciﬁcity for CCR8 but found no agonist activity against CCR2
(Luttichau et al., 2000). The chemotaxis studies provided little data on
individually cloned MC148R proteins (Damon et al., 1998; Krathwohl
et al., 1997). However, Luttichau et al. found MC148R1 to act as a
selective antagonist of CCR8 in binding, calcium mobilization, and
chemotaxis assays (Luttichau et al., 2000).
In addition to the two conserved N-terminal cysteines, MC148R1
contains two additional cysteines at its carboxyl terminus (residues 95
and 102). The primary amino acid sequences of all human CC
chemokines except for CCL21/SLC lack these additional C-terminal
cysteines (Arenberg et al., 2001). The deduced amino acid sequence of
mature MC148R1 predicted a shorter N-terminus (Senkevich et al.,
1996). Since the N-terminus of the chemokine is the region involved in
receptor activation, it was hypothesized that MC148R1 might function
as a chemokine antagonist (Senkevich et al., 1996). In support of this
hypothesis it was demonstrated that MC148R1 blocked the chemokine
response ofmonocytes toMIP-1α (Krathwohl et al., 1997) and inhibited
chemotaxis of human lymphocytes, and neutrophils in response to a
large number of CC andCXC chemokines (Damonet al., 1998).However,
the mechanism of MC148R1 antagonistic activity has not been
investigated. Additionally, the role of the N-terminal and C-terminal
cysteine residues in the observed biological activity ofMC148R1 has not
been investigated.
In this study we analyzed the mechanism of blocking the
chemokine response by MC148R1 and investigated the role of the
conserved N-terminal and the non-conserved C-terminal cysteines.
We demonstrate in two different assay systems that His-tagged
MC148R1 displaces the interaction between CXCL12α and CXCR4, and
that the N-terminal cysteines modulate this displacement. The results
suggest physical interaction with the chemokines as a mechanism for
the observed anti-chemokine activities of MC148R1.
Results
Construction, expression and puriﬁcation of the recombinant proteins
In order to investigate the mechanism of MC148R1 activity we
constructed a number of point mutations in its primary amino acid
structure. The ﬁrst mutant knocks out the two conserved N-terminal
cysteines and the next three knock out the additional C-terminal
cysteines in MC148R1 either individually or in combination (Fig. 1A).
We hypothesized that the additional C-terminal cysteines could cause
folding changes that would provide the MC148R1 protein its
antagonistic properties. Another point mutant was constructed that
changed the Leucine at residue 94 into arginine crating a consensus
BBXB domain found in CC chemokine. We hypothesized that creating
a BBXB domain might confer a chemotactic activity for the
chemokine-like protein MC148R1. Compared to other chemokines,
MC148R1 contains a signiﬁcantly shorter N-terminus preceding the
conserved cysteines. It has been hypothesized that the receptor
activation domain of the N-terminus found in other chemokines is
deleted from MC148R1, leaving only a receptor-binding domain that
is hypothesized to be responsible for the observed antagonisticactivities. We have generated a mutation (Δ26–30) with the ﬁrst ﬁve
amino acids deleted in order to create a non-functional mutant that
lacks the antagonistic activities.
To provide a reliable source for the MC148R1 and its mutants we
cloned the His-tagged construct into the bacterial expression vector
pET-32a (+). The CXCL12α coding sequence is separately cloned
within the same vector and therefore, serves as a positive control for
expression and puriﬁcation from E. coli (Altenburg et al., 2007). The
pET-32a vector contains the sequence coding for CXCL12α, MC148R1,
or mutant proteins along with a C-terminal His tag.
Silver-stained SDS-PAGE gels demonstrated that the high purity of
our bacterially expressed and His-afﬁnity puriﬁed proteins (Fig. 1B).
The silver-stained gel only shows wild type MC148R1 and CXCL12α
and two other cysteine mutants. The purity of other proteins used in
this study was basically similar and examined in other gels. Western
blot analysis using the His-tag antibodies as a probe demonstrated
expression of wild type and mutant proteins in bacteria (data not
shown). We have also constructed two recombinant vaccinia viruses
that encode either His-tagged MC148R1 or His-tagged CXCL12α.
Western blot analysis conﬁrmed the expression of either protein in
infected cells (Fig. 1C).
Anti-chemotactic activities of MC148R proteins
In order to examine the chemotactic activities of the MC148R
proteins we performed a chemotaxis assay where the chemokines are
incubated in the lower chamber and cells in the upper chamber. The
readout of this assay is the number of cells migrated into the lower
chamber. As expected, CXCL12α induced CEM cell migration (Fig. 2A),
and MIP-1α induced migration of peripheral blood mononuclear
cells (PBMCs) (Fig. 2B). MC148R1 blocked CXCL12α-induced (A) and
MIP-1α-induced (B) cell migration in a dose dependent manner. In
contrast, MC148R2 had no signiﬁcant effect on cell migration induced
by CXCL12α but signiﬁcantly inhibited cell migration induced by
MIP-1α (B). Mixing IL-8 with either MIP-1α or CXCL12α at similar
concentrations had no effect on cell migration by either chemokine
(Figs. 2A and B).
Similar chemotaxis experiments were performed to examine the
role of the conserved and the additional C-terminal cysteines in the
antagonistic activities of the MC148R1 protein. The experiments were
performed with CEM cells (Fig. 3A) and commercially available PBMCs
(Fig. 3B). The MC148R1 inhibitory effect on cell migration was only
abolished when the two conserved N-terminal cysteins were mutated
(Figs. 3A and B). The loss of the anti-chemotactic activity by C30/31A
mutant was consistent and was never observed with either the wild
typeHis-taggedMC148R1,wild typeMC148R2, C95A, C102A, C95/102A,
L94R, or theΔ26–30mutant proteins (Figs. 3A and B). The L94Rmutant
that acquired the BBXB domain did not induce chemotaxis (data not
shown). The IL-8 chemokine was used as a negative control for the
antagonistic activities of MC148R proteins. As shown in Figs. 3A and B,
IL-8 had no inhibitory effects on the chemotactic activities of CXCL12α
(Fig. 3A) or MIP-1α (Fig. 3B). The results demonstrate a signiﬁcant role
for the conserved N-terminal cysteines in the anti-chemotactic activity
observed with the His-tagged MC148R1.
Effect of MC148R1 and mutant proteins on CXCL12α-inhibition of Env-
mediated fusion
It is well established that CXCL12 inhibits HIV Env-mediated cell
fusion and viral entry of X4 strains (reviewed in (Alkhatib, 2009)). We
have previously demonstrated that the His-tagged CXCL12α was as
functional in blocking X4 fusion as the commercially available
CXCL12α that lacks the C-terminal His-Tag (Altenburg et al., 2007,
2010). We next investigated the effects of His-tagged MC148R1 on
CXCL12-mediated inhibition of X4 fusion in a cell-based fusion assay.
To determine whether the His-tagged MC148R1 affects CXCL12α-
AB C
Fig. 1. A) The predicted amino acid sequences of mature human MIP-1β/CCL4, wild-type MC148R1, and mutated MC148R1. Amino acid sequences are indicated by capital letters
with added methionine residues in lower case. All puriﬁed proteins contain a carboxyl terminal 6-histidine tag that is not depicted. Mutations are indicated as the amino acid before
mutation, followed by the numerical position based on the precursor protein, and the resulting amino acid after mutation. Bold letters indicate the mutated amino acid residues.
Asterisks indicate deleted amino acids. BBXB domains are underlined. Dashes have been added in order to align the cysteine residues. B) Silver stained SDS-PAGE of bacterially
expressed and His-afﬁnity puriﬁed chemokines. Approximately 0.5 μg of puriﬁed protein was loaded in each lane. The concentration of the total cell lysates was not determined. One
μl of the total 10 ml lysate (Total lys) was loaded. (C) Western blot analysis of MCV and CXCL12α/SDF-1α proteins expressed by recombinant vaccinia viruses. HeLa cells were
infected with WR (control vector), vCXCL12α, or vMC148R1 and cell lysates were prepared and fractionated in SDS-PAGE and blotted. The blots were probed with polyclonal anti-
histidine tag antibodies or anti-CXCL12-speciﬁc monoclonal antibodies. The blots were washed, reacted with HRP-conjugated secondary antibodies and blots exposed to X-ray after
reacting with the substrate.
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Fig. 2. Anti-chemotactic activity of His-tagged MC148R1 and MC148R2. The chemotactic activities of the His-tagged MC148R1 and MC148R2 were examined in a two-chamber
chemotaxis assay. All chemokines used were from R&D except for the His-tagged MC148R1 and its mutants. Chemotaxis assays were performed as outlined in Materials and
methods. The effect on CXCL12α-induced chemotaxis was analyzed in CEM cell (A) while effects on MIP-1α-induced chemotaxis was analyzed using peripheral blood mononuclear
cells (PBMCs) purchased from StemCell Technologies (B). Approximately 2×105 cells in a volume of 0.1 ml were added to each transwell membrane. The chemokines (100 ng/ml)
with or without the MCV proteins (at the indicated concentration) were added to the lower chamber in a 0.6 ml volume. The results are represented as the number of cells migrated
into the lower chamber. This experiment is representative of at least four other experiments performed in duplicates.
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Fig. 3. Anti-chemotactic activity of MC148R1 and the role of the cysteine residues. The
chemotactic activities of the indicated chemokine proteins were examined in a two-
chamber chemotaxis assay. All chemokines used were from R&D except for the MC148R1
and its mutants. Chemotaxis assayswere performed as outlined inMaterials andmethods
with CEM T cells. Approximately 2×105 cells in a volume of 0.1 ml were added to each
transwell membrane. The chemokines (100 ng/ml) with or without the MCV proteins
(100 ng/ml) were added to the lower chamber in a 0.6 ml volume. A) Commercial
CXCL12αusedwith CEMcells. B) CommercialMIP-1αwith peripheral bloodmononuclear
cells. Error bars indicate standard deviations of mean values obtained from triplicate
assays. This experiment is representativeof threeexperiments doneat different timeswith
different MC148R1 puriﬁcation sets. The chemokine inhibition activities of MC148R1 and
the respective mutations are reported as the percent migration of cells that were
stimulated with CXCL12α alone. A baseline value for spontaneous cell migration in the
absenceofCXCL12αorMIP-1αwascalculated tobe less than1%of the cellsmigrated in the
presence of the chemokine. The results are represented as the number of cells migrated
into the lower chamber. This experiment is representative of at least three other
experiments performed in duplicates.
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Fig. 4. MC148R1 inactivates the antiviral activity of CXCL12α. A) Puriﬁed MC148R1 or
its mutants were mixed with puriﬁed CXCL12α and incubated with the target TZM-bl
cells for 1 h at 37 °C before mixing with X4 Env-expressing cells and incubating for
2.5 h. The effect of the chemokine mixture on HIV-1 Env-mediated fusion was
measured by β-gal production. B) The CXCR4+CCR5+ TZM-bl cells expressing
vaccinia virus-encoded T7 RNA polymerase were used as target cells. The TZM-bl cells
expressing T7 RNA polymerase were either infected with recombinant vaccinia viruses
encoding MC148R1 or CXCL12α or co-infected with both recombinant viruses. Effector
HeLa cells were coinfected with recombinant vaccinia virus encoding the PT7-lacZ
reporter gene and vaccinia virus encoding the X4 LAV Env. The infected target cells
were mixed with Env-expressing cells and the extent of Env-mediated cell fusion was
measured by β-gal production. The Western Reserve (WR) vector strain was used as a
control for virus infection. The results are representative of at least three different
experiments performed in duplicate. Error bars indicate standard deviations of mean
values obtained from duplicate wells.
452 Q. Jin et al. / Virology 417 (2011) 449–456mediated blocking of X4 fusion we performed experiments involving
incubating mixtures of MC148R1 or mutant proteins and CXCL12α
with the target cells before challenging with Env-expressing cells. As
expected, pre-treating the target cells with afﬁnity-puriﬁed CXCL12α
alone resulted in efﬁcient inhibition of X4 Env-mediated fusion
(Fig. 4A). This inhibitory activity was not observed with either
MC148R1 or the afﬁnity-puriﬁed vector-transformed bacterial lysates.
Pre-treatment of the target cells with a mixture of CXCL12α and
MC148R1, C95/102A, L94, or Δ26–30 abolished the inhibitory activity
of CXCL12α. In contrast, pre-treatment of the target cells with a
mixture of CXCL12α and C30/31A had no effect on the inhibitory
activity of CXCL12α (Fig. 4A). The results demonstrate that the
conserved N-terminal cysteines are critical for MC148R1 to inactivate
the observed inhibitory activity of CXCL12α. The two additional
cysteines at the C-terminus do not seem to be involved in the critical
structure needed for the observed MC148R1 activity.
To demonstrate the biological activity of the His-tagged MC148R1
in mammalian cells we used recombinant vaccinia viruses to expressthe His-tagged CXCL12α and His-tagged MC148R1 either individually
or co-express them in the target cells. Expression of CXCL12α in the
target cells caused signiﬁcant blocking of X4 Env-mediated fusion.
Interestingly, the blocking effect of CXCL12α was abolished upon co-
expressing the MC148R1 protein in the same target cell population
(Fig. 4B). Cells co-expressing CXCL12α andWRwere used as a control
for multiple virus infection and did not result in abolishing the
blocking effect of CXCL12α. These results provided strong evidence
for the inactivation effect of MC148R1 on CXCL12α antiviral activity.
This evidence has been provided through co-expressing the native
proteins in mammalian cells. Taken together, these observations
further conﬁrm the inhibitory effect of MC148R1 on CXCL12α binding
with CXCR4.
Physical interaction of MC148R1 and CXCL12α
To determine whether MC148R1 and CXCL12α physically interact
we co-infected NIH 3T3 cells with recombinant vaccinia viruses
expressing either protein. Immunoprecipitation (IP) with anti-
MC148R1 antibodies and immunoblotting and probing with anti-
bodies to either protein showed the expected expression of MC148R1
and CXCL12α protein bands in cells infected with either virus (Fig. 5).
High molecular weight band representing heterodimers were only
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Fig. 5. Physical interaction ofHis-taggedMC148R1 and CXCL12α. HeLa cellswere infected or co-infectedwith the indicated viruses. Following 16 h incubation of infected cells at 31 °C, cell
lysates were prepared and immunoprecipitated with anti-MC148R1 antibodies (Panels A, B, and C) or immunoprecipitated with anti-CXCL12α (Panels D, E, and F), fractionated on
SDS-PAGEand immunoblotted. Theblotwas probedwith anti-His antibodies (Panels A andD), stripped, reprobedwithanti-MC148R1 antibodies (Panels B&E), strippedandﬁnally probed
with anti-CXCL12α antibodies (Panels C & F). Following primary antibody reactions the blots were washed and probed with anti-rabbit (MC148R1 or His tag antibodies) or anti-mouse
(CXCL12α) antibodies conjugated to HRP. The blots were exposed to X-ray ﬁlm after reacting with the HRP substrate.
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Fig. 6. Binding analysis of CXCL12α in the absence and presence ofMC148R proteins. Cold
CXCL12α alone or mixed with equivalent amounts of the indicated proteins at increasing
concentrations were incubated for 30 min at room temperature. A ﬁxed amount of
I−125-labeled CXCL12α (10 ng/ml)was added to each chemokinemixture then added to
CEM cells. The cell-chemokine mixtures were incubated at 4 °C for 1 h and then washed
three times with PBS-0.1% BSA. The cell pellet-associated counts were measured in a
gamma counter. The 0 ng/ml point represents the bindingof I−125-labeledCXCL12α alone
with no cold chemokine added. The results are representative of three different
experiments performed in triplicates. CPM, counts per minute.
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(Figs. 5A–F). IP with MC148R1 antibodies or anti-CXCL12α antibodies
then immunoblotting with Anti-His antibodies revealed the expected
chemokine proteins and a high molecular weight band (Figs. 5A and
D). Stripping and re-probing the blot with anti-MC148R1 identiﬁed
the bands speciﬁc to the MC148R1 protein (Figs. 5B and E). Re-
stripping and re-probing the blot with anti-CXCL12α antibodies
identiﬁed the CXCL12α-speciﬁc protein bands (Figs. 5C and F). The
results demonstrate physical interaction between MC148R1 and
CXCL12α.
MC148R1 but not MC148R2 displaces CXCL12α binding
To determine whether physical interaction with chemokine altered
binding of CXCL12α to CXCR4 we performed experiments where
control IL-8, MC148R1, MC148R2, C30/31A, or C95/101A were mixed
with cold CXCL12α. The mixtures were incubated at room temperature
for 30 min then 10 ng/ml of I−125-labeled CXCL12αwas added to each
protein mixture. The mixtures containing the I−125-labeled CXCL12α
were then added to CEM cells. The controls in this experiment were
either cold CXCL12α or cold CXCL12α+IL-8 at increasing concentra-
tions of cold proteins. We have previously determined that binding of
CXCL12α to CEM cells is very sensitive to AMD3100 indicating it is
mediated through CXCR4 (Altenburg et al., 2007, 2010). The results
show that cold CXCL12α alone or mixed with IL8, C30/31A and
MC148R2 had no signiﬁcant effect on the binding afﬁnity of CXCL12α.
However, thebindingwas signiﬁcantly reduced in thepresenceof either
MC148R1 or C95/101A. For example, in the MC148R1+cold CXCL12α
or C95/101A+cold CXCL12α mixtures higher concentrations of
cold CXCL12α were required to result in 50% displacement of bound
125I-CXCL12α (Fig. 6). We consistently observed at least a 4–5 timeshigher binding afﬁnity for CXCL12α alone or treatedwith IL-8, C30/31A,
MC148R2 than cold CXCL12α treated with MC148R1 or C95/101A
(Fig. 6). Reduced binding afﬁnitywas observed as a result ofmixing cold
CXCL12α with C95/101A but not with C30/31A (Fig. 6). These results
demonstrate that interaction of CXCL12α with MC148R1 but not
MC148R2 results in the displacement of CXCL12α by reducing the
chemokine's binding afﬁnity.
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Chemokines are deﬁned by four invariant cysteine residues in their
N-termini that form disulﬁde bonds (reviewed in (Fernandez and
Lolis, 2002)). The ﬁrst cysteine in the sequence forms a covalent bond
with the third, and the second cysteine forms a disulﬁde bond with
the fourth cysteine. The chemokine-like proteins MC148R1 and
MC148R2 are the only viral chemokine homolog that has been
shown to inhibit chemotaxis of multiple leukocyte subsets induced by
CC and CXC chemokines (Damon et al., 1998; Krathwohl et al., 1997).
In contrast, another study found no inhibition of chemotaxis of
monocytes, lymphocytes and neutrophils using several CC and CXC
chemokines (Luttichau et al., 2000). MC148R1 and MC148R2 are
among the few virally encoded chemokine homologues that contain
two additional cysteines in their C-termini. vMIP-III encoded by KSHV
has 6 cysteines in its primary sequence, but the additional two
cysteines are placed at different positions. We hypothesized that the
two additional cysteines might provide the optimal structure for the
MC148R1 to act as a chemokine antagonist. Our results demonstrated
that mutating the two extra C-terminal cysteines had no signiﬁcant
effect on the antagonistic activity of MC148R1. In contrast, mutating
the conserved N-terminal cysteines in MC148R1 resulted in the loss of
its functions in terms of inhibiting chemotaxis and abolishing
CXCL12α-mediated X4 fusion. We show for the ﬁrst time that
vaccinia-expressed MC148R1 abolished the CXCL12α-mediated inhi-
bition of HIV Env-mediated cell fusion. The results suggested that the
determinants of MC148R1 involved in blocking chemotaxis might
overlapwith those involved in inhibiting CXCL12α-mediated blocking
of X4 fusion.
The results reported here are not due to the fact that our proteins
contain an N-terminal methionine and a C-terminal His-tag or due to
any protein impurities that might represent a minor population of
molecules that get eluted form the His-afﬁnity columns. Several lines
of evidence are provided to support our conclusions. First, we have
previously demonstrated that met-CXCL12α-His-Tag was functional-
ly indistinguishable from the commercially available CXCL12α that
lacks the ﬁrst methionine and the His-tag (Altenburg et al., 2007,
2010). Among the seven mutants of MC148R1 protein treated and
puriﬁed the same way the only mutant that lost the MC148R1
antagonistic function was the C30/31A mutant. The other six mutants
of MC148R1 were always functional in terms of blocking chemotaxis.
Second, we have demonstrated that our puriﬁcation procedure results
in N90% pure chemokines as visualized by silver-stained gels.
Finally, several of the commercially available chemokines also contain
C-terminal His-tags. For example, the met-CXCL16-His-tag sold by
R&D systems is functionally indistinguishable from the met-CXCL16-
Flag (Flag sequence, DYKDDDDK) puriﬁed on Flag-afﬁnity columns
(Matloubian et al., 2000; Wilbanks et al., 2001).
The core of the chemokine structure is stabilized largely by the
two disulﬁdes and by hydrophobic interactions from one side of the
C-terminal helix and a portion of the β-sheet (reviewed in (Fernandez
and Lolis, 2002)). Previous studies have demonstrated that alanine
mutagenesis of any of the cysteines of CXCL8 (IL-8) leads to loss of
structure and function. The results of our current study demonstrated
that the loss of the antagonistic function of MC148R1 resulted from
mutating the conserved N-terminal cysteines. This suggested a critical
role for the conserved cysteines and the N-terminus of MC148R1 in
the observed antagonistic functions. Since the N-terminal cysteines
form disulﬁde bonds with the third and fourth cysteines it is likely
that mutating either of the conserved N-terminal cysteines will have a
similar effect to our double cysteine mutant.
The ﬁrst evidence for the importance of the N-terminus for the
chemokine activity came from studies with IL-8, which binds with high
afﬁnity to CXCR1 and CXCR2 (reviewed in (Loetscher and Clark-Lewis,
2001)). It has been demonstrated by mutagenesis and by selective
substitution or deletion that the chemotactic activity of IL-8 criticallydepends on the Glu-Leu-Arg residues, the so-called ELR motif,
immediately preceding the ﬁrst cysteine (reviewed in (Loetscher and
Clark-Lewis, 2001)). The ELR motif is a characteristic feature of all CXC
chemokines that act through CXCR1 and/or CXCR2. It contributes to the
high-afﬁnity binding and is the receptor-triggering moiety of the
molecule. The CXCL12α, however, lacks the ELR motif and its
chemotactic activity against CXCR4-expressing cells had been deter-
mined to be within the ﬁrst eight N-terminal residues (reviewed in
(Loetscher andClark-Lewis, 2001)). As amechanismfor theantagonistic
activity of MC148R1 we propose physical interaction and masking the
chemokine's functional N-terminus that is critical for binding the
chemokine receptor. In support of this hypothesis we demonstrated
decreased binding afﬁnity of CXCL12αwhen mixed with MC148R1 but
not with MC148R2.
The chemotaxis results reported in this study are in agreement with
the previously published data by Damon et al. and Krathwohl et al.
(Damon et al., 1998; Krathwohl et al., 1997) but not by Lattichau et al.
who reported a selective blocking of CCR8-mediated chemotaxis by
MC148R1 (Luttichau et al., 2000). It is hard to reconcile all the previous
literature since every study was different in terms of the source of the
MC148R1 protein and the target cells used in the different assays.
However, our study is theﬁrst to report thatMC148R2doesnot block
CXCL12α-mediated chemotaxis. The primary amino acid sequence of
MC148R2 indicates 10 non-homologous residues when compared to
MC148R1 (Krathwohl et al., 1997). It is possible that these residues
contributed to the loss of CXCL12α-mediated chemotaxis byMC148R2.
The ten non-homologous amino acid residues in MC148R1 and
MC148R2 proteins might account for the observed difference in their
biological activities. Detailedmutational analysis of both proteinsmight
provide insight into the different functional domains involved.
Since N-terminal deletions in several homologous CC chemokines
abolished their function we examined the effect of deleting the ﬁrst 5
residues on MC148R function (reviewed in (Loetscher and Clark-Lewis,
2001)). The Δ26–30 MC148R1 mutant is a deletion of the ﬁrst 5 amino
acids after the signaling peptide and before the conserved cysteines. The
idea behind doing this was that MC148R1 has a much shorter amino
terminus than the other functional chemokines. We reasoned the
shorter amino terminus resulted in efﬁcient binding to the receptor but
a lack of signaling through the receptor,making it a receptor antagonist.
Our results showed that this N-terminal deletion (Δ26–30) was as
functional as thewild typeMC148R1 in termsof its antagonistic activity.
The results suggested no critical role for the ﬁrst ﬁve N-terminal
residues of MC148R1 in its antagonistic activity.
It has been previously demonstrated that the BBXB motif of
RANTES is the principal site for heparin binding and controls receptor
selectivity (Proudfoot et al., 2001). Since the MC148R1 primary amino
acid sequence does not contain any BBXBmotifs we hypothesized that
introducing a BBXB motif might change the functional properties of
this chemokine-like protein. L94R mutation introduced a BBXB
domain in a homologous location in RANTES. Although the L94R
bound better to mammalian cells (data not shown) it did not induce
chemotaxis but preserved its wild type antagonistic function. Among
all the MC148R1 constructs described in this study only the C30/31A
mutant lost the antagonistic function. Even though MC148R1 is a
chemokine-like protein it does not act as a chemokine, however, its
antagonistic function is lost by the loss of the conserved cysteines
whose loss in the CC chemokine results in the loss of the chemotactic
function. The structural determinants involved in the antagonistic
activities of MC148R1 remain to be investigated.
Materials and methods
Cells and antibodies
The HeLa, NIH 3T3, and LM (tk-) cell lines were maintained in
Dulbecco Modiﬁed Eagle Medium (DMEM; Quality Biologicals,
455Q. Jin et al. / Virology 417 (2011) 449–456Gaithersburg, MD) containing 10% fetal bovine serum (FBS) and
antibiotics. The CEM T Lymphoblast cell line was maintained in RPMI-
1640 containing 10% FBS and antibiotics. Peripheral blood mononu-
clear cells were purchased from StemCell Technologies.
Polyclonal antibodies against the MC148R1 protein were generated
in rabbits against a KLH-conjugated peptide corresponding to the
C-terminus of the protein (HKDLCPQIWSGCESL). The immunizations
and serum collections were performed by Sigma Genosys (Sigma, TX).
Monoclonal antibodies to CXCL12αwere purchased from R&D Systems.
Anti-His antibodies were purchased from Santa Cruz Biotechnology.
Construction of recombinant vaccinia viruses encoding MC148R1 or
CXCL12α
The cDNA encoding MC148R1 was obtained from Dr. Bernard
Moss, LVD, NIAID, NIH. Construction of recombinant vaccinia viruses
encoding either His-tagged MC148R1 or CXCL12α protein was
performed as previously described (Agrawal et al., 2004; Broder and
Earl, 1999). Brieﬂy, the cDNA fragment encoding the MC148R1
protein was inserted into pSC59 under the strong vaccinia virus
early/late promoter and transfected into TK-cells that have been
infected with the Western Reserve (WR) wild-type strain of vaccinia
virus. WR was used as a negative vector control that does not encode
any foreign protein. Positive plaques were identiﬁed by dot blot
hybridization using P32-labeledMC148 cDNA. After 3 cycles of plaque
puriﬁcation on TK-cells virus stocks were prepared by infecting HeLa
cells and frozen at −70 °C until used.
Puriﬁcation of E. coli expressed recombinant His-tagged chemokines
We transfected the recombinant pET-32a/CXCL12α or pET-32a/
MC148R1 vectors into AD494 (DE3) pLysS E. coli host for optimal
expression. We have previously described the construction, expres-
sion, and puriﬁcation of CXCL12 variants (Altenburg et al., 2007,
2010). Brieﬂy, transformed bacteria harboring each recombinant
plasmid were isolated into single colonies. A single colony was picked
from each sample and used to inoculate 5 ml of LB containing the
antibiotics 100 μg/ml ampicillin, and 30 μg/ml chloramphenicol and
incubated at 37 °C with shaking for 12–16 h. The culture was then
centrifuged for 5 min at 5000 g and the supernatant discarded. The
bacterial pellets were resuspended in 500 ml LB containing 50 μg/ml
ampicillin and grown until the optical density (at wavelength
600 nm) of the cultures reached 0.6. At this point, isopropyl β-D-
thiogalacto-pyranoside (IPTG) was added to a ﬁnal concentration of
0.6 mM and incubated at 30 °C for 4 h to induce expression of
recombinant proteins. The cultures were placed on ice for 5 min and
the bacterial cells harvested by centrifugation. The cells were then
frozen at −70 °C until ready to use.
Bacterial pellets were suspended in 5 ml lysis buffer per pellet and
rotated at room temperature for 1 h. The lysates were then centrifuged,
and the pellets containing inclusion bodies were denatured in buffer
containing 6 M guanidine-HCl. The clariﬁed supernatants were poured
onto a Ni-NTA histidine-binding column (Sigma, St. Louis, MO)
equilibrated with 10 column volumes of denaturing binding buffer.
Both ends of the column were immediately capped and the columns
were rotated at 4 °Covernight. The denaturedproteinswere refolded on
the column by a stepwise removal of the denaturant as previously
described (Matsumoto et al., 2003). The columns were washed with
decreasing levels of urea, followed by increasing levels of imidazole to
remove non-speciﬁc bacterial contaminants. The proteins were eluted
with 2 ml elution buffer, and the elution buffer was exchanged for
phosphate buffered saline (PBS) on a PD-10 desalting column. Protein
concentrations were quantiﬁed by the Bradford assay (Bio-Rad,
Hercules, CA), and analyzed for size and purity by SDS-PAGE. The
proteins were also analyzed by western blotting using a polyclonal
antibody to the histidine tag that is present in all constructs (Santa CruzBiotechnology, Inc., Santa Cruz, CA). The relative concentrations of the
puriﬁed proteins were converted to nanomolarity by using the
predicted molecular weight of each recombinant.
Chemotaxis assays
Chemotaxis assays were performed as previously described by our
group (Altenburg et al., 2007, 2010). Brieﬂy, for CXCL12α-mediated
chemotaxis CEM T lymphoblast cells were suspended in chemotaxis
medium (Iscove's Modiﬁed Dulbecco's Medium (IMDM)) supplemen-
ted with 0.5% bovine serum albumin (BSA) at a density of
2×106 cells/ml. The puriﬁed CXCL12α (100 nM) with or without wild
type or mutant MC148R1 (100 nM) was suspended in chemotaxis
medium. The suspended mixtures (in 0.6 ml) were ﬁrst added to the
wells of a 24-well plate followed by a 5-micron pore transwell
membrane to each well (Costar, Corning Incorporated, Acton, MA).
The cells were added to the inside of the transwell membrane at a
volume of 0.1 ml (2×105 cells). The plates were then capped and
incubated for four hours at 37°/6% CO2. After the incubation period, the
transwell membranes were removed from the wells and the migrated
cells counted by ﬂow cytometry. For MIP-1α-mediated chemotaxis we
used commercially available PBMCs (StemCell Technologies).
PBMCs were resuspended in Dulbecco's minimal essential medium
(GIBCO/BRL)with antibiotics at a density of 2×106/ml. Chemotaxiswas
assayed as described above.
HIV-1 Env-mediated cell fusion assay
HIV-1 Env-mediated fusion was performed by a vaccinia-based
reporter assay as previously described (Agrawal et al., 2004). Brieﬂy,
the target CD4+CXCR4+CCR5+ TZM-bl cells (AIDS Reagent Program,
Bethesda, Maryland) (Chackerian et al., 1997) were infected by
vaccinia virus encoding the bacteriophage T7 RNA polymerase.
Effector HeLa cells were co-infected by PT7-lacZ vaccinia virus (lacZ
reporter gene under the T7 promoter) and vaccinia virus encoding
either the X4 LAV Env, or the control Unc, an uncleaved HIV-1 Env that
has its cleavage site mutated and therefore cannot engage in
membrane fusion. The Unc Env is used to measure the non-speciﬁc
background in the fusion assay. The target cells were plated in a 96
well plate at 1×105 cells per well and treated for one hour with either
CXCL12α alone or a mixture of CXCL12α and MC148R1 protein or its
mutants at 10 μg/ml each. After one hour incubation at 37°/6% CO2,
the Env-expressing HeLa cells were mixed with the target cells at 1:1
ratio. The cell mixtures were incubated for 2.5 h at 37 °C then lysed
and the substrate chlorophenolred-β-D-galactopyranoside (CPRG)
was added. The extent of cell fusion was assayed by measuring
β-galactosidase produced. In other Env-mediated fusion experiments
the vaccinia viruses encoding either CXCL12α or MC148R1 were used
to express the chemokines.
Immunoprecipitation and immunoblotting
NIH 3T3 cells were either infected with recombinant vaccinia
viruses vMC148R1 or vCXCL12α or co-infected with both viruses. The
optimum time of expression of each protein was determined by time
course experiments and found to be 16 h post-infection. Cytoplasmic
extracts were cleared and prepared for immunoprecipitation exper-
iments. Cell lysates were immunoprecipitated with polyclonal
antibodies (puriﬁed IgG fraction) speciﬁc for the MC148R1 or
monoclonal antibodies to CXCL12α and proteins fractionated on a
15% SDS-PAGE. The gel was blotted and the blot sequentially probed
with anti-His, stripped and re-probed with anti-MC148R1 antibodies,
stripped then probedwith anti-CXCL12α antibodies. The blots probed
with anti-MC148R1 rabbit antibodies were washed and reacted with
anti-rabbit-HRP conjugated antibodies. Following washing and
456 Q. Jin et al. / Virology 417 (2011) 449–456reacting with the HRP substrate the blot was exposed and to X-ray
ﬁlm and developed.
Binding assays
Direct binding experiments involved the use of 125I-labeled
CXCL12α (home-made using standard labeling procedures) and
cold recombinant CXCL12α and MCV proteins. Cold CXCL12α alone
or mixed with IL-8, MC148R1, MC148R2, C30/31A, or C95/101A were
incubated for 30 min at room temperature then 125I-labeled CXCL12α
added to each mixture. The new chemokine mixtures containing
10 ng/ml 125I-labeled CXCL12α (speciﬁc activity of 2200 Ci/mmol)
were then added to CEM cells (1 million cells/tube, in triplicate). The
cell-chemokine mixtures were incubated at 4 °C for 1 h and then
washed three times with PBS-0.1% BSA. The cell pellet-associated
counts were measured in a gamma counter and 125I-labeled CXCL12α
binding measure in counts per minute (CPM).
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